Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Efficacy and safety of sildenafil citrate (Viagra®) for the treatment of erectile dysfunction in men in Egypt and South Africa

Abstract

The efficacy of sildenafil citrate (Viagra®), an oral agent for the treatment of erectile dysfunction (ED), has been demonstrated in global studies. This 12-week randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study assessed the efficacy and safety of sildenafil to treat ED in men in Egypt and South Africa. Men with ED of varied etiology were randomized to receive sildenafil 50 mg (n=128) or placebo (n=126); doses could be adjusted to 100 or 25 mg. Questions from the International Index of Erectile Function (IIEF) assessing the ability to achieve (Q3) and maintain (Q4) erections demonstrated a significant improvement with sildenafil compared with placebo (P<0.0001). Improved erections were reported by 74% of patients receiving sildenafil and 27% of those receiving placebo (P<0.0001). Headache, dyspepsia, and flushing were the most common adverse events in sildenafil-treated patients. These results are consistent with clinical trials in other countries. We conclude that sildenafil is an efficacious and well-tolerated treatment for men with ED in Egypt and South Africa.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3

References

  1. NIH Consensus Conference on Impotence. Impotence. Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.

  2. Aytac IA, McKinlay JB, Krane RJ . The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50–56.

    Article  Google Scholar 

  3. United Nations. World population prospects 1996. United Nations Population Division, New York: Department of Public Information Publications Department, 1997.

  4. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  PubMed  Google Scholar 

  5. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.

    Article  CAS  PubMed  Google Scholar 

  6. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A . Outcome analysis of goal directed therapy for impotence. J Urol 1996; 155: 1609–1612.

    Article  CAS  PubMed  Google Scholar 

  7. Steers WD . Viagra—after one year. Urology 1999; 54: 12–17.

    Article  CAS  PubMed  Google Scholar 

  8. Sadovsky R, Miller T, Moskowitz M, Hackett G . Three-year update of sildenafil citrate (Viagra®) efficacy and safety (Eng). Int J Clin Pract 2001; 55: 115–128.

    CAS  PubMed  Google Scholar 

  9. Glossman H, Petrischor G, Bartsch G . Molecular mechanisms of the effects of sildenafil (VIAGRA®). Exp Gerontol 1999; 34: 305–318.

    Article  Google Scholar 

  10. Corbin JD, Francis SH . Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999; 274: 13729–13732.

    Article  CAS  PubMed  Google Scholar 

  11. Zusman RM, Morales A, Glasser DB, Osterloh IH . Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83 (Suppl 5A): 35C–44C.

    Article  CAS  PubMed  Google Scholar 

  12. Montorsi F et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999; 53: 1011–1018.

    Article  CAS  PubMed  Google Scholar 

  13. Ugarte F . Treatment with VIAGRA® (sildenafil citrate) for erectile dysfunction is efficacious and well tolerated in Mexican men. Poster presented at: Sociedad LatinoAmericana para el Estudio de la Impotencia, Mexico City, October 30, 1999.

  14. Meng TH, for the ASSESS-1 Study Group. Asian Sildenafil (VIAGRA®) Efficacy and Safety Study for erectile dysfunction (ASSESS): preliminary results for Malaysia, Philippines, and Singapore. Abstract presented at: Fourth Asian Congress in Urology, Singapore, September 17–20, 1998.

  15. Taher A, for the ASSESS-2 Study Group. Asian Sildenafil (VIAGRA®) Efficacy and Safety Study for erectile dysfunction (ASSESS): preliminary results for Hong Kong, Indonesia, and Thailand. Abstract presented at: Fourth Asian Congress in Urology, Singapore, September 17–20, 1998.

  16. Rendell MS, Rajfer J, Wicker PA, Smith MD . Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 421–426.

    Article  CAS  PubMed  Google Scholar 

  17. Olsson AM, Persson CA . Efficacy and safety of Viagra® (sildenafil citrate) in men with cardiovascular disease and erectile dysfunction. J Am Coll Cardiol 2000; 35 (Suppl A): 329A.

    Google Scholar 

  18. Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  PubMed  Google Scholar 

  19. Dinsmore WW et al. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53: 800–805.

    Article  CAS  PubMed  Google Scholar 

  20. Levinson B . Erectile dysfunction and culture in South Africa. J Sex Marital Ther 1999; 25: 267–270.

    Article  CAS  PubMed  Google Scholar 

  21. Modebe O . Erectile failure among medical clinic patients. Afr J Med Sci 1990; 19: 259–264.

    CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a research grant from Pfizer Inc. Participants in the African Sildenafil Study Group included MAM Abdel Aal, MD; Said Abdel Azim, MD; Wael Abu Fad, MD; Luigi Aldera, MD; MS Bornman, MD; Gary Burgess, MD; Magdy A El Akkad, MD; Adel H El-Behairy, MD; M Hatem El-Bialy, MD; Moustafa El-Demiry, MD; Eman H El-Morsi, MD; Mohammad El-Gallad, MD; Ahmed M El-Taher, MD; MAH Habib, MD; AAL Hegazy, MD; Goolam M Hoosen, MD; Ismail M Khalaf, MD; Mohammad Koth, MD; Bernard Levinson, MD; Ivan P Levinson, MD; Irving Lissoos, MD; Kamal ZM Shaeer, MD; Bahgat A Metawea, MD; Sherif Mourad, MD; Johannes H Naude, MD; MAK Omar, MD; Simon Reif, MD; Mac Robertson, MD; A Carel Schmidt, MD; David O Smart, MD.

Author information

Authors and Affiliations

Authors

Consortia

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Levinson, I., Khalaf, I., Shaeer, K. et al. Efficacy and safety of sildenafil citrate (Viagra®) for the treatment of erectile dysfunction in men in Egypt and South Africa. Int J Impot Res 15 (Suppl 1), S25–S29 (2003). https://doi.org/10.1038/sj.ijir.3900970

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900970

Keywords

  • Africa
  • erectile dysfunction
  • men
  • sildenafil

This article is cited by

Search

Quick links